Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

Withdrawn before enrolling

Conditions studied: Diabetes, Type 1

In brief

The investigators' primary aim is to determine the impact of using hybrid closed-loop (HCL) system in patients with type 1 diabetes (T1D) and end stage renal disease (ESRD) prior to kidney transplantation. The investigators will also determine whether HCL, by improving glucose control, will affect short-term (1 month) and long-term (12 months) complications after kidney transplantation in patients with T1D.

Key facts

Study ID

NCT03494010

Run by

Yale University

People needed

0

Starts

2018-08-31

Expected to finish

2021-04-30

Last updated by the study team

2021-03-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 1 diabetes
• Recipient of (historical controls) or on waiting list for (cohort) a living donor kidney transplant.

You may not qualify if…

• Cohort and Historical Controls:
• Vision, hearing impairment (patients cannot recognize the pump and sensor signals and alarms)
• Cognitive impairment (unless 24-hour caregiver is available)
• Total daily insulin dose requirements less than 8 units per day
• Patients who are not willing to check their blood glucose test at least twice a day
• Not followed/do not plan be followed at Yale New Haven Hospital
• Cohort:
• No living donor candidate

Where it is running

• Yale-New Haven Organ Transplant Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.